Does Medicare Advantage Cover Rybelsus?

How Medicare Advantage Handles Rybelsus Coverage

Medicare Advantage (MA) plans that include Part D prescription drug benefits can cover Rybelsus when prescribed for its FDA-approved indication: type 2 diabetes mellitus. The FDA label for Rybelsus specifies oral semaglutide as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Coverage depends on the specific MA-PD plan a beneficiary selects during open enrollment. Each plan maintains its own formulary, negotiates its own rebates with Novo Nordisk, and sets its own utilization management requirements. A 2023 CMS analysis found that 89% of Medicare Part D formularies listed at least one GLP-1 receptor agonist, though formulary placement varied widely [1]. Some plans place Rybelsus on Tier 3 (preferred brand) with a copay between $35 and $95 per month after the deductible, while others assign it to Tier 4 (non-preferred brand) with coinsurance of 25% to 33%. The difference can mean hundreds of dollars per month in out-of-pocket cost.

Beneficiaries should check their plan's formulary on Medicare.gov before assuming coverage. Formulary placement can change at the start of each plan year.

Why Weight-Loss Coverage Is Denied

This is the single largest source of confusion. Rybelsus is not FDA-approved for weight management, and CMS has historically excluded anti-obesity medications from Part D coverage under the Social Security Act, Section 1862(a)(1)(A) [2]. That exclusion remains in effect for Rybelsus regardless of which MA carrier issues the plan.

A limited exception emerged in March 2024 when the FDA granted Wegovy (subcutaneous semaglutide 2.4 mg) a supplemental indication for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight [3]. Some Part D plans began covering Wegovy under that cardiovascular indication. Rybelsus does not carry this indication. The SELECT trial (N=17,604) that supported the cardiovascular label expansion studied injectable semaglutide 2.4 mg, not oral semaglutide [4]. Prescribers who attempt to obtain Rybelsus coverage by citing weight loss as the primary goal will receive a denial.

If a patient has both type 2 diabetes and obesity, the prescriber should list type 2 diabetes as the primary diagnosis on the prior authorization form. The weight-loss benefit is secondary and does not need to appear as the reason for prescribing.

Prior Authorization: What Plans Require

Nearly every MA-PD plan requires prior authorization (PA) before covering Rybelsus. The PA process exists to confirm that the patient meets clinical criteria and that less expensive alternatives have been tried or are inappropriate.

Common PA criteria across major MA carriers include a confirmed diagnosis of type 2 diabetes (ICD-10 E11.x), a recent HbA1c value (typically 7.0% or higher), documented trial and failure of, or intolerance to, metformin (unless contraindicated), and prescribing by or in consultation with an endocrinologist or primary care provider managing diabetes. Some plans also require documentation that the patient has tried a sulfonylurea or an SGLT2 inhibitor before approving a GLP-1 receptor agonist.

The American Diabetes Association's Standards of Care (2024) recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [5]. Citing this guideline in the PA submission strengthens the case for approval, particularly when the patient has cardiovascular comorbidities.

PA turnaround times vary. Federal rules require MA plans to issue a standard decision within 72 hours and an expedited decision within 24 hours when a delay could seriously harm the patient [6].

Step Therapy Requirements

Step therapy (also called "fail first") is common. Plans want evidence that a patient tried metformin, the least expensive first-line oral diabetes drug, before moving to Rybelsus at $998 per month.

A typical step therapy sequence looks like this. Step one: metformin monotherapy for at least 90 days. Step two: metformin plus a sulfonylurea or SGLT2 inhibitor for 60 to 90 days. Step three: if HbA1c remains above target, the plan authorizes a GLP-1 receptor agonist such as Rybelsus. Some plans allow step two to be skipped if the patient has documented cardiovascular disease, because the ADA guidelines support early GLP-1 RA use in that population [5].

Patients who were already taking injectable semaglutide (Ozempic) and want to switch to oral Rybelsus may face a separate PA, even though the active molecule is identical. The plan may treat the switch as a new therapy rather than a continuation.

Prescribers can request a step therapy exception if the patient has a clinical reason to bypass earlier steps. Valid reasons include metformin intolerance (GI side effects are reported in up to 25% of users per a Cochrane review [7]), renal impairment with eGFR below 30 mL/min/1.73m², or a documented allergy.

Formulary Tier and Cost Breakdown

Where a plan places Rybelsus on its formulary determines the patient's share of the cost. Medicare Part D formularies use a standard tier structure.

Tier 1 covers generics at the lowest copay. Tier 2 covers preferred generics. Tier 3 is preferred brand, typically $35 to $100 copay. Tier 4 is non-preferred brand, often 25% to 33% coinsurance. Tier 5 is specialty, with coinsurance of 25% to 33% and additional utilization management.

Most MA-PD plans place Rybelsus on Tier 3 or Tier 4. A Kaiser Family Foundation analysis of 2024 Part D formularies found that GLP-1 receptor agonists were placed on non-preferred brand or specialty tiers in 61% of plans surveyed [8]. Plans that negotiated larger rebates from Novo Nordisk tend to place Rybelsus on Tier 3 with a lower copay.

During the catastrophic coverage phase (after $8,000 in true out-of-pocket spending in 2025 under the Inflation Reduction Act cap), beneficiaries pay $0 for covered Part D drugs [9]. For patients who reach that threshold early in the year, Rybelsus becomes free for the remaining months.

The PIONEER-4 trial (N=711) compared oral semaglutide 14 mg to subcutaneous liraglutide 1.8 mg and placebo in adults with type 2 diabetes. At 52 weeks, oral semaglutide reduced HbA1c by 1.2 percentage points from baseline compared to 0.2 for placebo (P<0.001) and produced 4.4 kg mean weight loss versus 0.5 kg for placebo [10]. These efficacy data support the clinical rationale for Rybelsus when a prescriber needs to justify coverage on appeal.

The Manufacturer Savings Card and Medicare

Novo Nordisk offers a savings card for Rybelsus that can reduce costs to as little as $10 per month for commercially insured patients. Medicare beneficiaries cannot use it. The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits manufacturer copay assistance for patients enrolled in federally funded programs, including Medicare Part D [11].

Some patients attempt to use GoodRx or similar discount programs instead of their Part D benefit. This is allowed, but spending through discount cards does not count toward the Part D out-of-pocket threshold, which delays reaching the catastrophic coverage phase. Patients should do the math carefully.

Novo Nordisk does operate a Patient Assistance Program (PAP) for uninsured or underinsured patients. Medicare beneficiaries who meet income thresholds (generally below 400% of the federal poverty level) may qualify, but enrollment requires demonstrating that the Part D plan does not adequately cover the drug [12].

How to Appeal a Rybelsus Denial

Denials happen. A plan might deny Rybelsus because the PA paperwork was incomplete, step therapy was not documented, or the plan's pharmacy benefit manager classified the request as off-label for weight loss. The appeal process has five levels under federal Medicare rules [6].

Level 1: Plan Redetermination. The prescriber submits additional clinical documentation to the plan. The plan must respond within 7 calendar days (72 hours if expedited). Include the patient's full medication history, lab values (HbA1c, fasting glucose, renal function), comorbidities, and a letter of medical necessity citing ADA guidelines.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case goes to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews the clinical evidence independently. The decision is due within 7 calendar days.

Level 3: Office of Medicare Hearings and Appeals (OMHA). An administrative law judge hearing, available if the amount in controversy meets the threshold ($185 in 2025).

Level 4: Medicare Appeals Council. A paper-based review.

Level 5: Federal district court. Rarely reached for prescription drug appeals.

Most Rybelsus denials are resolved at Level 1 or Level 2. The CMS Medicare Appeals System Statistics show that approximately 56% of Part D redetermination requests resulted in at least partial reversal in 2023 [13]. The key is thorough documentation at Level 1.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Barriers to accessing GLP-1 receptor agonists, including excessive prior authorization requirements, undermine the ability of clinicians to follow evidence-based guidelines for type 2 diabetes management" [14]. This sentiment is echoed in a 2024 ADA position statement calling for reduced administrative burden in diabetes medication access [14].

Oral Semaglutide vs. Injectable Options Under Medicare

Some patients prefer the convenience of a daily tablet over weekly injections. Others are directed to Rybelsus by their plan's formulary, which may prefer oral over injectable formulations or vice versa.

Ozempic (injectable semaglutide, 0.5 mg, 1 mg, or 2 mg weekly) is FDA-approved for type 2 diabetes and carries the same active ingredient as Rybelsus. The PIONEER-7 trial demonstrated that flexible-dose oral semaglutide achieved similar HbA1c reductions compared to sitagliptin 100 mg, with 1.3 percentage point reduction versus 0.8 for sitagliptin at 52 weeks [15]. Plans that prefer Ozempic over Rybelsus may require the patient to try the injectable first, or vice versa.

The 2023 Endocrine Society clinical practice guideline on pharmacological management of obesity notes that "oral semaglutide at the 50 mg dose under investigation may offer a non-injectable option for weight management, but the currently approved 14 mg dose for diabetes has more modest weight-loss effects" [16]. Medicare coverage decisions will continue to evolve as new formulations and indications reach the FDA.

Tips for Maximizing Coverage

Work with the prescriber's office to submit a complete PA on the first attempt. Incomplete PAs are the most common reason for initial denials, not clinical ineligibility.

Request a formulary exception if Rybelsus is on a non-preferred tier. Plans are required to grant tier exceptions when the prescriber demonstrates that preferred alternatives are medically inappropriate. Document specific reasons: "Patient experienced symptomatic hypoglycemia on glipizide" or "Patient has stage 3b CKD, eGFR 38, metformin contraindicated."

Review the plan's Evidence of Coverage (EOC) document, available on the plan's website or by calling the member services number on the back of the insurance card. The EOC lists every drug on the formulary, the tier, quantity limits, and PA requirements.

Consider switching MA-PD plans during the Annual Election Period (October 15 through December 7) if the current plan places Rybelsus on an unfavorable tier. The Medicare Plan Finder allows side-by-side comparison of drug costs across plans in the beneficiary's ZIP code.

Patients with low income may qualify for the Medicare Part D Low-Income Subsidy (LIS, also called Extra Help), which reduces copays to $4.50 for generics and $11.20 for brand-name drugs in 2025 [9]. LIS eligibility is determined by the Social Security Administration.